Precision medicine in pancreatic cancer: treating every patient as an exception

Area of Science:

• Oncology
• Precision Medicine
• Cancer Genomics

Background:

• Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), has not seen survival improvements from precision medicine, unlike other cancers.
• Research into PDAC precision therapies is abundant, but progress is hindered by a lack of agents targeting common genetic alterations.
• Existing transcriptional classifications of PDAC require prospective validation and new treatment options to demonstrate clinical value.

Purpose of the Study:

• To identify actionable genetic and phenotypic alterations in pancreatic cancer for precision therapy development.
• To bridge the gap in precision medicine for PDAC by learning from breakthroughs in other cancer types.
• To establish consensus on actionable targets and facilitate the identification of exceptional responders in PDAC.

Main Methods:

• Review of current research on PDAC genetic and phenotypic alterations.
• Analysis of precision medicine strategies in other malignancies for potential application to PDAC.
• Conceptual framework for developing knowledge and tools for real-time identification of exceptional PDAC patients.

Main Results:

• The primary challenge for PDAC precision medicine is the lack of consensus on actionable targets, not the absence of such targets.
• Identifying exceptional responders could significantly improve PDAC patient outcomes.
• Translating discoveries from other cancers may offer new avenues for PDAC treatment.

Conclusions:

• Developing consensus on actionable targets is crucial for advancing precision medicine in PDAC.
• Tools and knowledge dissemination are needed for clinicians to identify exceptional PDAC patients and optimize management.
• Real-time feedback from clinical outcomes is essential for refining PDAC subgroup classifications and treatment strategies.